^
    3d
    AGAVE-201: A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (clinicaltrials.gov)
    P2, N=296, Recruiting, Syndax Pharmaceuticals | Active, not recruiting --> Recruiting
    Enrollment open
    |
    CSF1 (Colony stimulating factor 1)
    |
    Niktimvo (axatilimab-csfr)
    8d
    HMPL-012-SPRING-P105: Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Trial completion date: May 2026 --> Dec 2026
    Trial completion date
    |
    gemcitabine • albumin-bound paclitaxel • Sulanda (surufatinib)
    8d
    HMPL-012-SPRING-OS101: Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=47, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Sulanda (surufatinib)
    8d
    HMPL-012-SPRING-NEN109: A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=6, Terminated, Changhai Hospital | N=100 --> 6 | Trial completion date: Nov 2026 --> Jun 2026 | Not yet recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Jun 2026; This investigator-initiated study closed to recruitment early due to slower-than-anticipated patient accrual.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Sulanda (surufatinib)
    9d
    Axatilimab + CAR-T for High-Risk Lymphoma (clinicaltrials.gov)
    P1, N=29, Not yet recruiting, Northside Hospital, Inc.
    New P1 trial
    |
    Niktimvo (axatilimab-csfr)
    14d
    NAHL: Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, University of Utah | Trial completion date: Apr 2028 --> Nov 2028 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Niktimvo (axatilimab-csfr)
    21d
    Combined treatment of TROP‑2 targeted CAR-T and vascular disruptor CBP enhances anti‑tumor activity in triple‑negative breast cancer. (PubMed, Transl Oncol)
    Our findings demonstrated the potential of TROP-2 as a viable target for CAR-T therapy in breast cancer. The combination of TROP-2 CAR-T cells with CBP not only enhances the therapeutic efficacy but also maintains a favorable safety profile, offering a promising new strategy for the treatment of breast cancer.
    Journal • IO biomarker
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    sotuletinib (BLZ-945)
    21d
    Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=32 --> 17
    Enrollment closed • Enrollment change
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • adrixetinib (Q702)
    21d
    A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas (clinicaltrials.gov)
    P3, N=136, Not yet recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd
    New P3 trial
    |
    Avastin (bevacizumab) • hydroxyurea • SYHA1813
    23d
    Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Sulanda (surufatinib)
    28d
    INCA34176-254: A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease (clinicaltrials.gov)
    P2, N=130, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Jakafi (ruxolitinib) • prednisone • Niktimvo (axatilimab-csfr)
    1m
    Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov)
    P2, N=96, Recruiting, Dragonboat Biopharmaceutical Company Limited | Not yet recruiting --> Recruiting
    Enrollment open